Utility of Serum Anti-Müllerian Hormone Measurement as Part of Polycystic Ovary Syndrome Diagnosis.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analytic methodology
PubMed 38776986 · doi:10.1055/s-0044-1786731
What was done
The authors reviewed the 2023 international evidence-based guidelines and related literature regarding the utility of serum anti-Müllerian hormone (AMH) measurement as an alternative to gynecological ultrasound for identifying polycystic ovary morphology (PCOM) in polycystic ovary syndrome (PCOS) diagnosis, examining factors affecting AMH levels and reported diagnostic cut-offs.
What was found
The abstract provides no numerical data, diagnostic cut-off values, or statistical metrics. It reports that while AMH is a usable diagnostic tool for PCOM, no single universal cut-off exists because values vary based on the specific AMH assay used, physiological factors (age, ethnicity, obesity), and iatrogenic factors (hormonal medications, ovarian surgery).
Why it matters
Incorporating serum AMH as an alternative to pelvic ultrasound allows PCOS diagnostic workups to occur more readily in primary care and non-gynecological settings where ultrasound access may be limited.
Limits
As a narrative review, it presents no original data, sample size figures, or systematic quantitative synthesis. The abstract lacks specific diagnostic accuracy metrics, numerical cut-offs, or assay-specific reference ranges.
Cited by
- supports The diagnostic criteria for PCOS require meeting at least two out of three criteria: hyperandrogenism symptoms/elevated androgens, ovulatory dysfunction/irregular periods, and polycystic ovarian morphology on ultrasound or elevated AMH.